All In MedTech

FDA Clearance Tracker · P950019-S013

RAY TFC UNITE PRODUCT LINE

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jul 15, 2003 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jul 15, 2003

Approved

Time to decision

152 days

Received Feb 13, 2003. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class II

The decision

FDA number
P950019-S013
Device name
RAY TFC UNITE PRODUCT LINE
Applicant
Stryker Spine
Applicant location
Allendale, NJ
Received
Feb 13, 2003
Decided
Jul 15, 2003
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Express GMP Supplement
Original approval
P950019

Device type

Device class
Class II
Regulation
21 CFR 888.3080

Every decision under product code MAX

FDA's approval statement

As written in FDA's record.

APPROVAL FOR NEW MANUFACTURING FACILITIES FOR THE RAY TFC UNITE PRODUCT LINE. THE FACILITIES ARE LOCATED AT CENTERPULSE SPINE-TECH, MINNEAPOLIS, MINNESOTA AND BIOTEST LABORATORIES, INC., MINNEAPOLIS, MINNESOTA.

Source documents

Other decisions for Stryker Spine

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.